| # | Drug | Count |
|---|---|---|
| 0 | ADALIMUMAB | 359 |
| 1 | INFLIXIMAB | 164 |
| 2 | PREDNISONE | 113 |
| 3 | RISANKIZUMAB-RZAA | 102 |
| 4 | VEDOLIZUMAB | 102 |
| 5 | UPADACITINIB | 100 |
| 6 | ERGOCALCIFEROL | 70 |
| 7 | AZATHIOPRINE | 68 |
| 8 | METHOTREXATE SODIUM | 68 |
| 9 | USTEKINUMAB | 68 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | JOINT SUPPORT | 1 | 0.0500 |
| 1 | SODIUM CHLORIDE, SODIUM ACETATE ANHYDROUS, SODIUM GLUCONATE, POTASSIUM CHLORIDE, AND MAGNESIUM CHLORIDE | 1 | 0.0333 |
| 2 | METHENAMINE, SODIUM SALICYLATE | 1 | 0.0093 |
| 3 | INFLIXIMAB-DYYB | 30 | 0.0087 |
| 4 | CLEMASTINE FUMARATE | 9 | 0.0065 |
| 5 | METHENAMINE MANDELATE | 1 | 0.0053 |
| 6 | L DOPA | 1 | 0.0037 |
| 7 | BERBERIS VULGARIS, ISATIS TINCTORIA, MORINDA CITRIFOLIA, PETIVERIA TETRANDRA, SCHINUS MOLLE, THYMOLUM, UVA-URSI | 1 | 0.0034 |
| 8 | BEVACIZUMAB-BVZR | 2 | 0.0028 |
| 9 | ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE | 1 | 0.0027 |
| # | Drug class | Count |
|---|---|---|
| 0 | Tumor Necrosis Factor Blocker [EPC] | 267 |
| 1 | Corticosteroid [EPC] | 180 |
| 2 | Interleukin-23 Antagonist [EPC] | 172 |
| 3 | Integrin Receptor Antagonist [EPC] | 123 |
| 4 | Nonsteroidal Anti-inflammatory Drug [EPC] | 115 |
| 5 | Janus Kinase Inhibitor [EPC] | 100 |
| 6 | Proton Pump Inhibitor [EPC] | 83 |
| 7 | Purine Antimetabolite [EPC] | 71 |
| 8 | Provitamin D2 Compound [EPC] | 70 |
| 9 | Interleukin-12 Antagonist [EPC] | 68 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 7 | 0.0102 |
| 1 | Guanylate Cyclase-C Agonist [EPC] | 10 | 0.0048 |
| 2 | Provitamin D2 Compound [EPC] | 70 | 0.0024 |
| 3 | Sclerosing Agent [EPC] | 1 | 0.0022 |
| 4 | CD4-directed Blocking Antibody [EPC] | 1 | 0.0019 |
| 5 | Interleukin-23 Antagonist [EPC] | 172 | 0.0016 |
| 6 | Endoglycosidase [EPC] | 3 | 0.0016 |
| 7 | Neonatal Fc Receptor Blocker [EPC] | 7 | 0.0016 |
| 8 | Integrin Receptor Antagonist [EPC] | 123 | 0.0014 |
| 9 | Prostacycline [EPC] | 1 | 0.0011 |